Purchase this article with an account.
Linda Hrarat, Franck Fajnkuchen, valerie sarda, marouane boubaya, thyphaine grenet, chaine gilles, Audrey Giocanti; Efficacy and safety of ranibizumab in diabetic macular edema: real life study. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1890.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the efficacy and safety of ranibizumab in patients with vision loss secondary to diabetic macular edema (DME).
Retrospective analysis of consecutive patients with vision loss due to DME and treated with ranibizumab. All patients received a loading dose of 3 monthly injections followed by re-treatments on an as needed basis. Primary endpoint was the change in best-corrected visual acuity (BCVA) at 12 months. Secondary endpoints were the change in central retinal thickness (CRT) and number of intravitreal injections (IVI) at 12 months.
One hundred and six eyes of 78 patients were included. BCVA changed from 48.3 letters at baseline to 59 letters at 12 months (p <0.0001) (mean gain: +10.7 letters) and 38% of patients had a final BCVA >70 letters. CRT decreased from 519 μm at baseline to 355 μm at 12 months (p <0.0001). The threshold of the first quartile of the baseline VA was 40 letters. Patients with a baseline VA >40 letters had a higher final VA of 66 ± 14 letters vs 43 ± 18 letters for patients with a baseline VA ≤40 letters (p <0.0001). A mean number of 5.4 (3-10) IVI were administered.
This study conducted in a clinical setting confirms the results of previous randomized trials. The final BCVA was mainly impacted by the baseline BCVA, which supports the early treatment of DME before patients experience a severe vision loss.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only